| Kathryn M Beauchamp, MD | |
|
777 Bannock St, Mc 7782, Denver, CO 80204-4507 | |
| (303) 426-6000 | |
| Not Available |
| Full Name | Kathryn M Beauchamp |
|---|---|
| Gender | Female |
| Speciality | Neurosurgery |
| Experience | 28 Years |
| Location | 777 Bannock St, Denver, Colorado |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063441582 | NPI | - | NPPES |
| 20659016 | Medicaid | CO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | 36417 (Colorado) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Colorado Hospital Authority | Aurora, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Physicians Incorporated | 3476465667 | 2657 |
News Archive
Functionally deaf patients can gain normal hearing with a new implant that replaces the middle ear. The unique invention from the Chalmers University of Technology has been approved for a clinical study. The first operation was performed on a patient in December 2012.
Drug repositioning- taking known drugs and identifying new applications for them-is an attractive concept for speeding up the process of bringing drugs to human testing for unmet medical needs.
CNS Protein Therapeutics, Inc., a privately held biotechnology company developing first-in-class disease–modifying treatments that address the underlying cause of cell death associated with a wide range of diseases, has completed a corporate name change to Amarantus Therapeutics, Inc. ("Amarantus") and appointed prominent biotechnology industry executive, Martin D. Cleary, as Chief Executive Officer.
IRMA applauds the launch of the world's first-ever Phase II rectal microbicide trial. The Microbicide Trial Network's study, called MTN-017, will test a reduced glycerin formulation of tenofovir gel applied rectally.
› Verified 2 days ago
| Entity Name | Denver Health And Hospital Authority |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477569838 PECOS PAC ID: 4688583578 Enrollment ID: O20031105000211 |
News Archive
Functionally deaf patients can gain normal hearing with a new implant that replaces the middle ear. The unique invention from the Chalmers University of Technology has been approved for a clinical study. The first operation was performed on a patient in December 2012.
Drug repositioning- taking known drugs and identifying new applications for them-is an attractive concept for speeding up the process of bringing drugs to human testing for unmet medical needs.
CNS Protein Therapeutics, Inc., a privately held biotechnology company developing first-in-class disease–modifying treatments that address the underlying cause of cell death associated with a wide range of diseases, has completed a corporate name change to Amarantus Therapeutics, Inc. ("Amarantus") and appointed prominent biotechnology industry executive, Martin D. Cleary, as Chief Executive Officer.
IRMA applauds the launch of the world's first-ever Phase II rectal microbicide trial. The Microbicide Trial Network's study, called MTN-017, will test a reduced glycerin formulation of tenofovir gel applied rectally.
› Verified 2 days ago
| Entity Name | University Physicians Incorporated |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962461889 PECOS PAC ID: 3476465667 Enrollment ID: O20031105000375 |
News Archive
Functionally deaf patients can gain normal hearing with a new implant that replaces the middle ear. The unique invention from the Chalmers University of Technology has been approved for a clinical study. The first operation was performed on a patient in December 2012.
Drug repositioning- taking known drugs and identifying new applications for them-is an attractive concept for speeding up the process of bringing drugs to human testing for unmet medical needs.
CNS Protein Therapeutics, Inc., a privately held biotechnology company developing first-in-class disease–modifying treatments that address the underlying cause of cell death associated with a wide range of diseases, has completed a corporate name change to Amarantus Therapeutics, Inc. ("Amarantus") and appointed prominent biotechnology industry executive, Martin D. Cleary, as Chief Executive Officer.
IRMA applauds the launch of the world's first-ever Phase II rectal microbicide trial. The Microbicide Trial Network's study, called MTN-017, will test a reduced glycerin formulation of tenofovir gel applied rectally.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kathryn M Beauchamp, MD 777 Bannock St, Mc 7782, Denver, CO 80204-4507 Ph: () - | Kathryn M Beauchamp, MD 777 Bannock St, Mc 7782, Denver, CO 80204-4507 Ph: (303) 426-6000 |
News Archive
Functionally deaf patients can gain normal hearing with a new implant that replaces the middle ear. The unique invention from the Chalmers University of Technology has been approved for a clinical study. The first operation was performed on a patient in December 2012.
Drug repositioning- taking known drugs and identifying new applications for them-is an attractive concept for speeding up the process of bringing drugs to human testing for unmet medical needs.
CNS Protein Therapeutics, Inc., a privately held biotechnology company developing first-in-class disease–modifying treatments that address the underlying cause of cell death associated with a wide range of diseases, has completed a corporate name change to Amarantus Therapeutics, Inc. ("Amarantus") and appointed prominent biotechnology industry executive, Martin D. Cleary, as Chief Executive Officer.
IRMA applauds the launch of the world's first-ever Phase II rectal microbicide trial. The Microbicide Trial Network's study, called MTN-017, will test a reduced glycerin formulation of tenofovir gel applied rectally.
› Verified 2 days ago
Dr. Peter J Lennarson, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 2045 N Franklin St, Denver, CO 80205 Phone: 303-338-4545 | |
Edward H Maa, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 777 Bannock St, Mc 7782, Denver, CO 80204 Phone: 303-436-6000 | |
Dr. Jerzy Wayne Rokicki, M.D., PH.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 2045 N Franklin St, Denver, CO 80205 Phone: 303-338-4545 Fax: 303-344-7715 | |
Dr. Todd S Crawford, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 2045 N Franklin St, Denver, CO 80205 Phone: 303-338-4545 | |
Dr. Sean E Markey, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 850 E Harvard Ave Ste 255, Denver, CO 80210 Phone: 303-996-7555 Fax: 303-996-7556 | |
Dr. Saul S Schwarz, MD Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 2045 Franklin St, Denver, CO 80205 Phone: 303-338-4545 |